Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neuropharmacology
2015 Oct 01;97:376-82. doi: 10.1016/j.neuropharm.2015.04.009.
Show Gene links
Show Anatomy links
Heterologous expression and nonsense suppression provide insights into agonist behavior at α6β2 nicotinic acetylcholine receptors.
Post MR
,
Limapichat W
,
Lester HA
,
Dougherty DA
.
???displayArticle.abstract???
The α6-containing subtypes of the nicotinic acetylcholine receptor (nAChR) are localized to presynaptic terminals of the dopaminergic pathways of the central nervous system. Selective ligands for these nAChRs are potentially useful in both Parkinson's disease and addiction. For these and other goals, it is important to distinguish the binding behavior of agonists at the α6-β2 binding site versus other subtypes. To study this problem, we apply nonsense suppression-based non-canonical amino acid mutagenesis. We report a combination of four mutations in α6β2 that yield high-level heterologous expression in Xenopus oocytes. By varying mRNA injection ratios, two populations were observed with unique characteristics, likely due to differing stoichiometries. Responses to nine known nAChR agonists were analyzed at the receptor, and their corresponding EC50 values and efficacies are reported. The system is compatible with nonsense suppression, allowing structure-function studies between Trp149 - a conserved residue on loop B found to make a cation-π interaction at several nAChR subtypes - and several agonists. These studies reveal that acetylcholine forms a strong cation-π interaction with the conserved tryptophan, while nicotine and TC299423 do not, suggesting a unique pharmacology for the α6β2 nAChR.
Azam,
α-Conotoxin BuIA[T5A;P6O]: a novel ligand that discriminates between α6ß4 and α6ß2 nicotinic acetylcholine receptors and blocks nicotine-stimulated norepinephrine release.
2010, Pubmed,
Xenbase
Azam,
α-Conotoxin BuIA[T5A;P6O]: a novel ligand that discriminates between α6ß4 and α6ß2 nicotinic acetylcholine receptors and blocks nicotine-stimulated norepinephrine release.
2010,
Pubmed
,
Xenbase
Beene,
Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine.
2002,
Pubmed
,
Xenbase
Capelli,
Stable expression and functional characterization of a human nicotinic acetylcholine receptor with α6β2 properties: discovery of selective antagonists.
2011,
Pubmed
Corringer,
Nicotinic receptors at the amino acid level.
2000,
Pubmed
Dougherty,
In vivo incorporation of non-canonical amino acids by using the chemical aminoacylation strategy: a broadly applicable mechanistic tool.
2014,
Pubmed
,
Xenbase
Filatov,
The role of conserved leucines in the M2 domain of the acetylcholine receptor in channel gating.
1995,
Pubmed
,
Xenbase
Fonck,
Novel seizure phenotype and sleep disruptions in knock-in mice with hypersensitive alpha 4* nicotinic receptors.
2005,
Pubmed
,
Xenbase
Gerzanich,
"Orphan" alpha6 nicotinic AChR subunit can form a functional heteromeric acetylcholine receptor.
1997,
Pubmed
,
Xenbase
Gleitsman,
Long-range coupling in an allosteric receptor revealed by mutant cycle analysis.
2009,
Pubmed
,
Xenbase
Gotti,
Brain nicotinic acetylcholine receptors: native subtypes and their relevance.
2006,
Pubmed
Grady,
Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.
2010,
Pubmed
Holladay,
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
1997,
Pubmed
Hone,
α-Conotoxin PeIA[S9H,V10A,E14N] potently and selectively blocks α6β2β3 versus α6β4 nicotinic acetylcholine receptors.
2012,
Pubmed
,
Xenbase
Hone,
Positional scanning mutagenesis of α-conotoxin PeIA identifies critical residues that confer potency and selectivity for α6/α3β2β3 and α3β2 nicotinic acetylcholine receptors.
2013,
Pubmed
,
Xenbase
Jha,
Energy and structure of the M2 helix in acetylcholine receptor-channel gating.
2009,
Pubmed
Kracun,
Influence of the M3-M4 intracellular domain upon nicotinic acetylcholine receptor assembly, targeting and function.
2008,
Pubmed
Kuryatov,
Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses.
2000,
Pubmed
,
Xenbase
Kuryatov,
Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers.
2011,
Pubmed
,
Xenbase
Le Novère,
The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences.
2002,
Pubmed
Letchworth,
Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors.
2011,
Pubmed
Ley,
Efficient expression of functional (α6β2)2β3 AChRs in Xenopus oocytes from free subunits using slightly modified α6 subunits.
2014,
Pubmed
,
Xenbase
Miyazawa,
Structure and gating mechanism of the acetylcholine receptor pore.
2003,
Pubmed
Moroni,
alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine.
2006,
Pubmed
,
Xenbase
Nelson,
Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase
Papke,
Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras.
2008,
Pubmed
,
Xenbase
Puskar,
Probing the effects of residues located outside the agonist binding site on drug-receptor selectivity in the nicotinic receptor.
2012,
Pubmed
Quik,
Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.
2006,
Pubmed
Quik,
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.
2011,
Pubmed
Smart,
Synaptic neurotransmitter-gated receptors.
2012,
Pubmed
Srinivasan,
Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning.
2011,
Pubmed
Van Arnam,
Functional probes of drug-receptor interactions implicated by structural studies: Cys-loop receptors provide a fertile testing ground.
2014,
Pubmed
Wang,
Expression of cloned α6* nicotinic acetylcholine receptors.
2015,
Pubmed
,
Xenbase
Xiao,
Characterizing functional α6β2 nicotinic acetylcholine receptors in vitro: mutant β2 subunits improve membrane expression, and fluorescent proteins reveal responsive cells.
2011,
Pubmed
Xiu,
Nicotine binding to brain receptors requires a strong cation-pi interaction.
2009,
Pubmed
,
Xenbase
Yang,
Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.
2009,
Pubmed
Zoli,
Diversity of native nicotinic receptor subtypes in mammalian brain.
2015,
Pubmed